LP-184 (Lantern Pharma) is a next-generation alkylating agent designed to preferentially damage DNA in cancer cells that overexpress certain biomarkers or harbor mutations in DNA repair pathways, according to a Lantern Pharma-issued press release. Read more . . .
The FDA granted orphan drug designation to LP-184 for the treatment of pancreatic cancer.